SAN FRANCISCO—Tardive dyskinesia (TD) is strongly linked with older age, medical comorbidity, and hospitalizations, according to a study of US veterans with serious mental illness presented during a poster session at the American Psychiatric Association’s annual meeting.

Is there any rationale for using both deutetrabenazine (Austedo) and valbenazine (Ingrezza) at the same time? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.

Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.

Are medications for tardive dyskinesia effective in mild, moderate, or severe cases? Get the answer from Psych Congress cochair Rakesh Jain, MD, MPH.

Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry.

The availability of new drugs for tardive dyskinesia (TD) means clinicians have an increased responsibility to proactively screen for the disorder and treat it when detected, Psych Congress cochair Rakesh Jain, MD, MPH, said.

Low-frequency and rare genetic variants may play a role in the development of tardive dyskinesia (TD), suggests a preliminary study published in European Neuropsychopharmacology.

An analysis of blood serum has identified differences between patients with tardive dyskinesia (TD) and people who have not developed the movement disorder.

Researchers have developed a new scale to measure the impacts tardive dyskinesia has on patients and their caregivers, according to a poster abstract presented at Psych Congress 2017.

The US Food and Drug Administration has approved deutetrabenazine for the treatment of tardive dyskinesia in adults, Teva Pharmaceutical Industries announced.